Circular RNA Generation Technology Market Forecast 2025-2031: The $732 Million Platform Poised to Revolutionize Gene Therapy and Vaccine Development

Circular RNA Generation Technology Market Forecast 2025-2031: The $732 Million Platform Poised to Revolutionize Gene Therapy and Vaccine Development

By a 30-Year Veteran Industry Analyst

The explosive success of mRNA vaccines in combating the COVID-19 pandemic brought the therapeutic potential of RNA to the forefront of global biotechnology. Yet, even as linear mRNA platforms proved their mettle, a more stable and versatile class of RNA molecule was quietly advancing through research pipelines: circular RNA (circRNA). Unlike its linear counterpart, circRNA is characterized by a covalently closed loop structure, a conformation that confers exceptional resistance to exonuclease degradation and enables prolonged protein expression. Harnessing this molecule for therapeutic and research applications requires specialized capabilities—this is the domain of Circular RNA Generation Technology. It encompasses the suite of biotechnological processes, including RNA splicing and precise circularization techniques, designed to synthesize circRNA either in vitro or in vivo, providing an essential tool for exploring circRNA biology and unlocking its potential in gene therapy, vaccine development, and drug discovery . Leading market research publisher QYResearch announces the release of its latest report, “Circular RNA Generation Technology – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032.”

For CEOs of biotechnology companies, R&D directors in gene therapy and vaccine development, pharmaceutical executives scouting next-generation platforms, and investors tracking the cutting edge of RNA therapeutics, understanding this emerging market is a strategic necessity. According to QYResearch data, the global market for Circular RNA Generation Technology was valued at an estimated US$ 527 million in 2024. The growth trajectory reveals a steady and significant expansion as the technology matures and moves toward clinical application: the market is projected to reach a readjusted size of US$ 732 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period 2025-2031 . This growth, while currently reflective of a research-driven market, is poised to accelerate as key technological hurdles are overcome and circRNA-based therapeutics advance through clinical pipelines.

[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4690533/circular-rna-generation-technology

Product Definition: Engineering the Covalently Closed Loop

Circular RNA Generation Technology is not a single process but a portfolio of molecular biology techniques designed to create circRNA molecules with specific sequences and properties. The market is segmented by the primary locus of synthesis, each with distinct applications and technical challenges :

• In Vitro Circular RNA Generation Technology: This approach involves synthesizing linear RNA precursors in a cell-free system (using enzymatic transcription) and then circularizing them through methods such as self-splicing introns (e.g., using group I or group II introns) or enzymatic ligation with RNA ligases. This is the dominant method for producing circRNA for research, drug discovery, and as a candidate therapeutic. It offers high control over sequence purity and production scale but requires optimization to achieve high circularization efficiency and remove immunogenic byproducts.
• In Vivo Circular RNA Generation Technology: This more complex approach involves delivering a DNA template encoding a circularizable RNA precursor into cells. The circularization then occurs inside the cell using the host’s endogenous splicing machinery or co-delivered enzymes. This strategy is being explored for sustained, long-term therapeutic protein expression from a single genetic payload, but it faces significant challenges in delivery efficiency, control over circularization fidelity, and potential for off-target effects.

These technologies are being developed and applied across a range of high-value therapeutic areas :

• Infectious Diseases: Developing circRNA vaccines that could offer enhanced stability (reducing cold-chain dependence) and durable antigen expression compared to linear mRNA vaccines.
• Tumors (Oncology): Engineering circRNAs to express tumor antigens for cancer vaccines, to encode immunomodulatory proteins (like cytokines), or to deliver protein-based therapeutics directly to the tumor microenvironment.
• Rare Diseases: Utilizing circRNAs for protein replacement therapy in genetic disorders, where the prolonged expression from a stable circRNA could reduce the frequency of administration.
• Others: This includes applications in protein engineering, cellular reprogramming, and as research tools for studying gene regulation and circRNA biology itself.

Key Development Characteristics Shaping the Industry

1. The mRNA Platform Legacy: A Foundation and a Challenge
The success of linear mRNA therapeutics has laid a powerful foundation for circRNA. It has validated the concept of RNA as a drug, established manufacturing infrastructure (e.g., lipid nanoparticle (LNP) delivery), and created a receptive regulatory and investment environment. However, circRNA technology must also differentiate itself from the now-dominant linear platform. The core value proposition of circRNA lies in its superior stability (due to its closed loop) and its potential for prolonged protein expression. Early data suggests that circRNA can provide more durable protein production compared to linear mRNA, a critical advantage for applications like protein replacement therapy or vaccines requiring long-lasting immunity. The challenge for generation technology providers is to consistently achieve high-yield, high-purity circRNA synthesis that translates these theoretical advantages into demonstrable in vivo performance.

2. The Manufacturing Hurdle: Purity, Immunogenicity, and Scale
A primary technical bottleneck for the circRNA field is the development of robust, scalable, and cost-effective manufacturing processes. Current in vitro generation methods often result in a mixture of circular and linear RNAs, as well as other byproducts. Linear RNA contaminants can trigger unwanted innate immune responses via pattern recognition receptors (like RIG-I), potentially causing toxicity and reducing the efficacy of the intended circRNA therapeutic. Significant research is focused on developing purification methods—such as high-performance liquid chromatography (HPLC) or RNase R digestion—to remove linear contaminants and achieve high-purity circRNA preparations . Advances in circularization chemistry, including the development of more efficient ribozymes or optimized ligation conditions, are also critical for increasing yield and reducing manufacturing costs. Companies that can demonstrate a proprietary, scalable manufacturing process yielding ultra-pure circRNA will hold a significant competitive advantage.

3. The Convergence with Delivery Science: LNP and Beyond
The clinical success of any circRNA therapeutic is inextricably linked to its delivery. CircRNA, like its linear counterpart, is a large, negatively charged molecule that cannot efficiently enter cells on its own. The field is leveraging the advances in lipid nanoparticle (LNP) technology pioneered for mRNA vaccines and therapeutics. However, the different biophysical properties of circRNA (its structure and potentially different interactions with lipid components) may necessitate optimization of LNP formulations. Looking further ahead, targeted delivery vehicles—such as antibody-conjugated LNPs, polymeric nanoparticles, or viral-like particles—are being explored to deliver circRNAs to specific cell types (e.g., hepatocytes for protein replacement, T-cells for immunotherapy). The evolution of Circular RNA Generation Technology is proceeding in lockstep with these advances in delivery science.

4. The Intellectual Property Landscape: A New Frontier for Patent Claims
The intellectual property (IP) landscape for circRNA generation technology is nascent but rapidly becoming more contested. Key patent claims are being staked on fundamental methods of circularization (e.g., specific permuted intron-exon (PIE) constructs), on sequences of engineered circularization elements, and on compositions of matter covering specific circRNA therapeutics. The experience of the mRNA field, where foundational IP has shaped the competitive landscape and led to major licensing deals and litigation, serves as a powerful precedent. Start-ups and established companies alike are aggressively filing patents to secure their position in this emerging space. For investors and corporate strategists, the strength and freedom-to-operate of a company’s IP portfolio is a critical due diligence consideration. The issuance of key patents in the United States and Europe in late 2025 and early 2026 is likely to catalyze partnership and acquisition activity.

5. The Competitive Landscape: A Mix of Specialized Biotechs and Pharma Interest
The current market is characterized by a dynamic ecosystem of specialized biotechnology companies, many of which have emerged from leading academic research labs. Key players include Orna Therapeutics, which is pioneering engineered circRNAs for immuno-oncology; Circode and Chimera Therapeutics, focused on therapeutic applications; and RiboX Therapeutics, Therorna, and Geneseed, among others . These companies are competing to demonstrate the in vivo efficacy and safety of their circRNA candidates in animal models. Major pharmaceutical companies are closely monitoring the space, establishing research collaborations, and making strategic investments. The acquisition of promising circRNA platform companies by larger pharma players is a foreseeable trend as the technology approaches clinical proof-of-concept.

Future Outlook and Strategic Implications

Looking toward the 2031 forecast horizon, the strategic imperatives are clear.

• For CEOs and Technology Leaders, the immediate priority is to establish a robust and scalable manufacturing platform that delivers ultra-pure, high-yield circRNA. Demonstrating in vivo proof-of-concept for a lead therapeutic candidate in a high-value indication (e.g., an oncology or rare disease program) will be critical for attracting partnerships and investment. Building a strong and defensible IP portfolio is paramount.
• For Pharmaceutical Executives, the key is to strategically evaluate circRNA technology as a potential platform to address therapeutic challenges where linear mRNA falls short—particularly where durable protein expression is desired. Early-stage partnerships and licensing deals with leading platform companies offer a way to gain access to the technology while managing risk.
• For Investors, this market represents a high-potential, early-stage opportunity within the broader RNA therapeutics space. The 5.4% CAGR reflects the current research-focused market, but the potential for explosive growth upon successful clinical validation is significant. The key is to identify companies with a differentiated and scalable generation technology, a clear IP strategy, and a credible path toward clinical development.

In conclusion, Circular RNA Generation Technology is a foundational platform poised to underpin the next wave of RNA therapeutics. The path to a $732 million market by 2031 will be shaped by overcoming key manufacturing hurdles, securing intellectual property, and delivering the clinical data that will unlock the full potential of this remarkably stable and versatile molecule.

Contact Us:

If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp